Search

Sartorius Stedim Biotech.

Open

BrancheFinanzen

204.4 0.15

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

199.6

Max

206.7

Schlüsselkennzahlen

By Trading Economics

Einkommen

-23M

93M

Verkäufe

400K

745M

KGV

Branchendurchschnitt

81.348

27.489

EPS

1.18

Dividendenrendite

0.37

Gewinnspanne

12.43

Angestellte

10,030

EBITDA

-55M

201M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+19.66% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.37%

3.99%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.2B

19B

Vorheriger Eröffnungskurs

204.25

Vorheriger Schlusskurs

204.4

Nachrichtenstimmung

By Acuity

24%

76%

53 / 530 Ranking in Finance

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Sartorius Stedim Biotech. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

16. Okt. 2025, 21:10 UTC

Wichtige Markttreiber

Kezar Life Sciences Shares Surge After Break with FDA, Restructuring Plan

16. Okt. 2025, 19:03 UTC

Akquisitionen, Fusionen, Übernahmen

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- 2nd Update

16. Okt. 2025, 17:58 UTC

Akquisitionen, Fusionen, Übernahmen

Canada Signals Limited Concern Over U.S. Government Stakes in Canadian Miners -- Update

16. Okt. 2025, 17:12 UTC

Ergebnisse

Ray-Ban Maker EssilorLuxottica's Revenue Surges to Quarterly Record -- Update

16. Okt. 2025, 17:12 UTC

Akquisitionen, Fusionen, Übernahmen

Canada Signals Limited Concern Over US Government Stakes in Canadian Miners

16. Okt. 2025, 16:59 UTC

Akquisitionen, Fusionen, Übernahmen

Airbus's Takeover of Spirit AeroSystems Plants Gets French Antitrust Clearance

16. Okt. 2025, 23:44 UTC

Market Talk

Gold Climbs Amid Safe-Haven Demand -- Market Talk

16. Okt. 2025, 23:42 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Declines -- Market Talk

16. Okt. 2025, 23:42 UTC

Market Talk

Global Equities Roundup: Market Talk

16. Okt. 2025, 22:15 UTC

Ergebnisse

China Tower: Results Supported by Higher Contributions From Energy, Smart Tower Business >0788.HK

16. Okt. 2025, 22:15 UTC

Ergebnisse

China Tower 9-Mos Rev CNY74.32B Vs. CNY72.45B >0788.HK

16. Okt. 2025, 22:15 UTC

Ergebnisse

China Tower 9-Mos Net CNY8.71B Vs. Net CNY8.15B >0788.HK

16. Okt. 2025, 22:02 UTC

Market Talk

Global Equities Roundup: Market Talk

16. Okt. 2025, 22:02 UTC

Market Talk

Santos Drifts Into 'Oversold Territory' -- Market Talk

16. Okt. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16. Okt. 2025, 20:50 UTC

Market Talk
Ergebnisse

Health Care Roundup: Market Talk

16. Okt. 2025, 20:23 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. Okt. 2025, 20:23 UTC

Market Talk

Recession Risks to Push Canada Toward October Rate Cut -- Market Talk

16. Okt. 2025, 20:20 UTC

Ergebnisse

These Stocks Moved the Most Today: TSMC, Salesforce, HPE, F5, United Airlines, Travelers, J.B. Hunt, Praxis Precision, and More -- Barrons.com

16. Okt. 2025, 20:08 UTC

Akquisitionen, Fusionen, Übernahmen

Jack in the Box to Sell Del Taco With Big Markdown. The Stock Plunged. -- Barrons.com

16. Okt. 2025, 19:37 UTC

Akquisitionen, Fusionen, Übernahmen

Crypto Industry Dives Deeper Into Prediction Markets as Kraken Buys Exchange -- Barrons.com

16. Okt. 2025, 19:26 UTC

Ergebnisse

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16. Okt. 2025, 19:24 UTC

Market Talk

U.S. Natural Gas Falls on Mild Weather, Ample Storage -- Market Talk

16. Okt. 2025, 19:23 UTC

Market Talk

Oil Falls As Oversupply Concerns Outweigh India News -- Market Talk

16. Okt. 2025, 19:23 UTC

Ergebnisse

Oracle Weighs In on Cloud Margins. The Stock Is Rising. -- Barrons.com

16. Okt. 2025, 18:35 UTC

Market Talk
Ergebnisse

Charles Schwab Logs Another Quarter of Record Revenues, Earnings -- Market Talk

16. Okt. 2025, 18:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16. Okt. 2025, 18:31 UTC

Market Talk

Global Equities Roundup: Market Talk

16. Okt. 2025, 18:31 UTC

Market Talk

Charles Schwab Readies Spot Crypto Trading -- Market Talk

16. Okt. 2025, 16:57 UTC

Market Talk

Oil Futures Lose Ground as EIA Reports Crude Stock Build -- Market Talk

Sartorius Stedim Biotech. Prognose

Kursziel

By TipRanks

19.66% Vorteil

12-Monats-Prognose

Durchschnitt 222.5 EUR  19.66%

Hoch 240 EUR

Tief 194 EUR

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Sartorius Stedim Biotech. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

5

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

202.7 / 211.7Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

53 / 530 Ranking in Finanzen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
help-icon Live chat